Background/Objectives: Mental disorders pose a significant public health challenge, affecting millions worldwide. Given the limitations of current therapies, many patients experience inadequate responses and adverse effects. Intermittent hypoxia (IH) has demonstrated anxiolytic, antidepressant, and neuroprotective properties in various protocols. This study investigated the effects of acute IH (13% O2, 1 h), fluoxetine (FLX) and their combination on depression-like behavior, serum corticosterone, and inflammatory cytokine levels induced by acute restraint stress in C57BL/6 female mice. Methods: Behavioral assessments included the tail suspension test, forced swim test, and open field test. Results: The combined IH + FLX treatment exhibited a synergistic effect, reducing immobility time and increasing latency time, respectively, in the tail suspension test (46%, p = 0.0014; 73%, p = 0.0033) and forced swim test (56%, p = 0.0082; 48%, p = 0.0322) compared to the ARS group. Biochemical analysis revealed that individual and combined treatments significantly reduced most inflammatory interleukins by up to 96%. Corticosterone levels were reduced by 30% only in the IH group. Conclusions: These findings highlight the potential of a one-hour IH session, particularly when combined with fluoxetine, to alleviate depressive-like behaviors and exert anti-inflammatory effects, suggesting a promising therapeutic approach for depression.
The rise in psychotropic drug use among students, particularly in Veterinary Medicine, correlates with high rates of mental disorders like depression and anxiety, often exacerbated by academic stress. Factors such as high academic demands, emotional exhaustion, and poor sleep quality contribute to the increased use of medications like antidepressants and anxiolytics. However, in Brazil, there is limited research on the profile and factors associated with this drug use among veterinary students. This study aims to assess the prevalence, patterns, and associated factors of psychotropic drug use at the Federal University of Santa Maria. A descriptive-correlational cross-sectional study was conducted using a survey covering sociodemographic data and psychotropic drug use. A total of 245 students participated in this study. The collected data included age, sex, semester, physical activity, sleep quality, drug use, family income, place of birth, and residence. In total, 36.7% of students reported using psychotropic medications during their undergraduate studies, with 77.1% being women and 22.9% men. Additionally, 45.6% reported insufficient sleep, defined as 4 to 6 h per day. Inactive students had a 94.5% higher likelihood of using psychotropic medications. Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines were the most reported drug classes. The findings highlight the emotional and academic burden of veterinary education, underscoring the need for institutional actions that prioritize student mental health.
Major depressive disorder is a reality to an increasing number of individuals worldwide, yet, it is still poorly understood and its treatment remains lackluster. Due to the subpar success rates of traditional monoaminergic pharmacotherapy, new targets have been explored. Here, the behavioral effects of a single dose of moxidectin (MOX) (1,5 mg/kg, 0,1 mL/10g, s.c.), a drug capable of allosterically modulating GABAA channels, was evaluated in male Swiss mice by the tail suspension (TST), splash (SPT), open field and elevated plus maze tests between 24 and 48 h post injection. MOX was capable of significantly decreasing the immobility time in TST and increasing grooming time in SPT, suggesting an antidepressant effect. To further explain the molecular pathways underlying MOX's observed behavioral changes, neurotrophic factors and oxidative stress biomarkers were identified. An increase in brain-derived neurotrophic factor (Bdnf) mRNA was observed, possibly explaining the behavioral changes. An increase in total antioxidant capacity and glutathione S-transferase (GST) in the prefrontal cortex and a decrease of GST in the hippocampus of MOX-treated animals may have also contributed to these results. To our knowledge, this is the first study demonstrating the antidepressant-like effect of MOX in mice. While these results are preliminary, they’re promising. The utilization of GABAA modulators is an emerging and interesting new avenue to be explored in the treatment of neuropsychiatric ailments.